WILLIAM R. FRIEDENBERG, M.D.; JOSEPH J. MAZZA, M.D.; JOHN D. HINES, M.D.
This content is PDF only. Please click on the PDF icon to access.
To the editor: Recent position papers and editorials in the Annals have discussed the French-American-British (FAB) classification of acute myeloid leukemia (1-4). In addition to giving reproducible results, a classification of acute leukemia should allow more definitive treatment based on the classification. Complete remissions have been obtained by the Eastern Cooperative Oncology Group in 71% of patients using daunorubicin, cytarabine, and 6-thioguanine (DAT) (5). The time to recovery of the platelet count to greater than 100 000/mm3 in patients obtaining a complete remission was approximately 26 days and usually preceded the rise in neutrophil count (> 1000/mm3) (5). However, when
FRIEDENBERG WR, MAZZA JJ, HINES JD. Treatment of Acute Megakaryocytic Leukemia. Ann Intern Med. ;104:280–281. doi: 10.7326/0003-4819-104-2-280_2
Download citation file:
Published: Ann Intern Med. 1986;104(2):280-281.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use